Medicare Enrolled
Dr. Andrew Lipman, M.D.
Medical Oncology · Naples, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lipman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lipman? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Lipman
Dr. Andrew Lipman is a medical oncology in Naples, FL, with 20 years in practice. Based on federal Medicare data, Dr. Lipman performed 436,219 Medicare services across 7,969 unique beneficiaries.
Between the years covered by Open Payments, Dr. Lipman received a total of $41,107 from 90 pharmaceutical and/or device companies across 763 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Lipman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 2% volume in FL$ $41,107 industry payments
Medicare Practice Summary
Medicare Utilization ↗436,219
Medicare services
Top 2% in FL for medical oncology
7,969
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~21,811 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 106,080 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 47,000 | $43 | $137 |
| Filgrastim injection (Zarxio) for white blood cells | 37,980 | $0 | $2 |
| Nivolumab injection (Opdivo) | 34,340 | $24 | $72 |
| Azacitidine chemotherapy injection | 31,245 | $0 | $4 |
| Daratumumab injection (Darzalex) | 29,160 | $38 | $110 |
| Anti-nausea injection (aprepitant) | 26,780 | $1 | $5 |
| Oxaliplatin chemotherapy injection | 21,732 | $0 | $12 |
| Denosumab injection (Prolia/Xgeva) | 15,840 | $18 | $51 |
| Paclitaxel chemotherapy injection | 11,991 | $0 | $2 |
| Epoetin alfa injection (Procrit) for anemia | 8,430 | $6 | $23 |
| Dexamethasone injection (steroid) | 6,333 | $0 | $3 |
| Immune globulin infusion (Gammagard) | 5,886 | $36 | $108 |
| Complete blood count (CBC) with differential | 5,483 | $8 | $29 |
| Blood draw (venipuncture) | 5,112 | $8 | $9 |
| Injection, docetaxel, 1 mg | 4,695 | $0 | $7 |
| Injection, eflapegrastim-xnst, 0.1 mg | 4,620 | $27 | $116 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 4,162 | $23 | $185 |
| Injection, bortezomib, 0.1 mg | 3,628 | $4 | $113 |
| Anti-nausea injection (Aloxi/palonosetron) | 3,200 | $1 | $28 |
| Iron infusion (Monoferric) | 2,700 | $16 | $57 |
| Anti-nausea injection (ondansetron/Zofran) | 2,468 | $0 | $9 |
| Office visit, established patient (30-39 min) | 2,387 | $99 | $339 |
| Drug injection, under skin or into muscle | 1,356 | $11 | $69 |
| Injection, leucovorin calcium, per 50 mg | 1,226 | $3 | $12 |
| Injection of additional new drug or substance into vein | 1,193 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 1,190 | $103 | $378 |
| Injection, fluorouracil, 500 mg | 823 | $2 | $7 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 565 | $1 | $6 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 504 | $3 | $205 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 485 | $23 | $84 |
| Infusion, normal saline solution , 1000 cc | 430 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 426 | $50 | $189 |
| Office visit, established patient (20-29 min) | 403 | $67 | $239 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 401 | $58 | $205 |
| Injection, diphenhydramine hcl, up to 50 mg | 400 | $1 | $3 |
| Infusion into a vein for hydration, each additional hour | 391 | $10 | $42 |
| Injection, carboplatin, 50 mg | 388 | $2 | $41 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 379 | $18 | $59 |
| Injection, cisplatin, powder or solution, 10 mg | 372 | $2 | $13 |
| Infusion into a vein for hydration, 31-60 minutes | 346 | $26 | $156 |
| Administration of chemotherapy into vein, each additional hour | 301 | $23 | $79 |
| Cyclophosphamide, 100 mg | 297 | $16 | $79 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 291 | $16 | $56 |
| Injection, potassium chloride, per 2 meq | 290 | $0 | $4 |
| Office visit, established patient, complex (40-54 min) | 267 | $144 | $474 |
| Administration of additional new drug or substance into vein, 1 hour or less | 263 | $52 | $178 |
| Injection, zoledronic acid, 1 mg | 259 | $7 | $69 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 183 | $135 | $562 |
| Injection, magnesium sulfate, per 500 mg | 168 | $1 | $2 |
| Injection of drug or substance into vein | 161 | $29 | $156 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 149 | $26 | $89 |
| Administration of additional new drug or substance into vein using push technique | 141 | $45 | $170 |
| New patient office visit (45-59 min) | 115 | $123 | $453 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 113 | $138 | $637 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 108 | $1 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 101 | $16 | $56 |
| Administration of chemotherapy into vein using push technique | 92 | $80 | $303 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 88 | $3 | $11 |
| Automated urinalysis | 85 | $2 | $8 |
| New patient office visit, complex (60-74 min) | 81 | $177 | $585 |
| Drawing of blood for a medical problem | 69 | $69 | $277 |
| Red blood count, automated test | 34 | $4 | $10 |
| Red blood count automated, with additional calculations | 19 | $5 | $20 |
| New patient office visit (30-44 min) | 14 | $80 | $298 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
26.9% high complexity
69.6% medium
3.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$41,107
Total received (2018-2024)
Avg $5,872/year across 7 years
Top 15% in FL for medical oncology
90
Companies
763
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$14,771 (35.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$13,428 (32.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,909 (31.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,169
2023$8,821
2022$3,435
2021$3,518
2020$3,565
2019$17,035
2018$1,564
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Kyowa Kirin, Inc.
$10,750
AstraZeneca Pharmaceuticals LP
$4,795
Mylan Institutional Inc.
$3,940
AMAG Pharmaceuticals, Inc.
$3,849
Karyopharm Therapeutics Inc.
$2,288
BeiGene USA, Inc.
$1,976
E.R. Squibb & Sons, L.L.C.
$1,054
Novartis Pharmaceuticals Corporation
$1,014
PFIZER INC.
$873
Janssen Biotech, Inc.
$860
Celgene Corporation
$765
Merck Sharp & Dohme LLC
$756
Merck Sharp & Dohme Corporation
$573
Amgen Inc.
$498
Astellas Pharma US Inc
$486
Incyte Corporation
$462
GENZYME CORPORATION
$442
Genentech USA, Inc.
$441
Seagen Inc.
$426
GlaxoSmithKline, LLC.
$317
Takeda Pharmaceuticals U.S.A., Inc.
$315
Gilead Sciences, Inc.
$305
Bayer HealthCare Pharmaceuticals Inc.
$252
Lilly USA, LLC
$244
ARRAY BIOPHARMA INC
$225
Regeneron Healthcare Solutions, Inc.
$157
Daiichi Sankyo Inc.
$157
Myriad Genetic Laboratories, Inc.
$139
Bayer Healthcare Pharmaceuticals Inc.
$132
ABBVIE INC.
$128
NanoString Technologies, Inc.
$107
Dendreon Pharmaceuticals LLC
$107
EMD Serono, Inc.
$101
Kite Pharma, Inc.
$91
TerSera Therapeutics LLC
$85
Alexion Pharmaceuticals, Inc.
$80
Pharmacyclics LLC, An AbbVie Company
$72
Octapharma USA, Inc.
$70
ADC Therapeutics America, Inc.
$69
Pharmacosmos Therapeutics Inc.
$65
Rigel Pharmaceuticals, Inc.
$63
SOBI, INC
$63
Blueprint Medicines Corporation
$62
MorphoSys, US Inc.
$60
Sun Pharmaceutical Industries Inc.
$59
Agios Pharmaceuticals, Inc.
$58
Puma Biotechnology, Inc.
$56
Ipsen Biopharmaceuticals, Inc
$56
Teva Pharmaceuticals USA, Inc.
$55
Eisai Inc.
$55
AbbVie Inc.
$50
EISAI INC.
$50
JAZZ PHARMACEUTICALS INC.
$44
Genmab U.S., Inc.
$44
Acrotech Biopharma LLC
$41
Deciphera Pharmaceuticals Inc.
$40
Mirati Therapeutics, Inc.
$38
CTI BioPharma Corp.
$37
Jazz Pharmaceuticals Inc.
$37
PharmaEssentia USA Corporation
$36
Sumitomo Pharma America, Inc.
$36
Heron Therapeutics, Inc.
$35
PUMA BIOTECHNOLOGY, INC.
$32
GE HEALTHCARE
$32
Sirtex Medical Inc
$32
Alnylam Pharmaceuticals Inc.
$30
Iovance Biotherapeutics, Inc.
$29
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
SpringWorks Therapeutics, Inc.
$28
Sysmex Inostics Inc
$26
SERVIER PHARMACEUTICALS LLC
$24
Tempus AI, Inc
$23
Exelixis Inc.
$23
Taiho Oncology, Inc.
$20
Array BioPharma Inc.
$19
Aveo Pharmaceuticals, Inc.
$19
ImmunoGen, Inc.
$19
Seattle Genetics, Inc.
$19
Acceleron Pharma, Inc.
$18
TG THERAPEUTICS, INC.
$18
AVEO Pharmaceuticals, Inc.
$17
Aurobindo Pharma USA, Inc.
$15
Helsinn Therapeutics (U.S.), Inc.
$14
Pharmacyclics LLC, an AbbVie Company
$14
TAIHO ONCOLOGY, INC.
$14
INSYS Therapeutics Inc
$13
Myovant Sciences Inc.
$13
Clovis Oncology, Inc.
$12
Veracyte, Inc.
$12
Secura Bio, Inc.
$10
Top 3 companies account for 47.4% of total payments
Associated products mentioned in payments ›
ADCETRIS · ADVATE · ANDEXXA · AYVAKIT · Abraxane · Alecensa · Amtagvi · Avastin · BELEODAQ · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · Braftovi · CABLIVI · CALQUENCE · CARVYKTI · CERDELGA · CEREZYME · CINVANTI · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · ELAHERE · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERLEADA · EVENITY · Enhertu · Epkinly · Erleada · FERAHEME · FOTIVDA · FRUZAQLA · Fabhalta · Farydak · GAZYVA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INFLECTRA · INJECTAFER · INLYTA · INREBIC · INVOKAMET · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · Ogivri · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROSIGNA ASSAY · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RYBREVANT · RYDAPT · Reblozyl · Rezlidhia · Rubraca · SANCUSO · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SYNDROS · Stivarga · TABRECTA · TASIGNA · TECVAYLI · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tibsovo · Trodelvy · UKONIQ · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VONVENDI · VOTRIENT · VPRIV · Venclexta · Vonjo · Vyloy · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XGEVA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYKADIA · ZYNYZ · ZYTIGA · Zevalin · Zoladex · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (36%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $9 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
14
Per 100K population
3.6
County median income
$86,173
Nearest hospital
PHYSICIANS REGIONAL MEDICAL CENTER - PINE RIDGE
5.8 mi
5.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Lipman is a mixed practice specialist, with above-average Medicare volume (top 2% in FL), and high industry engagement (mixed engagement, top 15%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Lipman experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Lipman performed 106,080 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lipman receive payments from pharmaceutical companies?
Yes. Dr. Lipman received a total of $41,107 from 90 companies across 763 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lipman's costs compare to other medical oncologys in Naples?
Dr. Lipman's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lipman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Naples
Browse medical oncologys in Naples ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
Kyowa Kirin, Inc. Payments to Doctors
See all physicians who received payments from Kyowa Kirin, Inc..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Mylan Institutional Inc. Payments to Doctors
See all physicians who received payments from Mylan Institutional Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology